POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
November 30, 2022 15:01 ET | POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
AMR Logo.png
Patient Registry Software Market is Expected to Reach USD 2.50 Bn by 2031: Allied Market Research
October 10, 2022 12:30 ET | Allied Market Research
Portland, OR, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the Global Patient Registry Software Market generated $993.3 million in 2021, and is...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
September 20, 2022 21:31 ET | POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
radiomedix logo
RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
November 18, 2021 17:00 ET | RadioMedix Inc.
Houston, TX, Nov. 18, 2021 (GLOBE NEWSWIRE) -- RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II...
Algernon Logo 1.png
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
October 13, 2021 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Dermavant Logo Color Sig (002).png
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
December 03, 2019 08:00 ET | Dermavant Sciences, Inc.
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 ...
Eko Launches ‘Eko Home,' a Cardiac Remote Monitoring Application Enabling Powerful Drug-Data Combinations to Enhance Clinical Studies and Pharmaceutical Trials
July 25, 2019 13:00 ET | Eko
San Francisco, July 25, 2019 (GLOBE NEWSWIRE) -- Eko, a Silicon Valley-based digital health company applying machine learning in the fight against heart disease, today announced Eko Home, a...
Logo.jpg
Endonovo Therapeutics Hires David Clark as Vice President of Sales
May 03, 2019 09:20 ET | Endonovo Therapeutics, Inc.
Los Angeles, May 03, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his new...
Study Finds Variations in Percentage of Clinical Teams Using Simple and Complex Adaptive Trial Designs
September 04, 2017 19:16 ET | Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - September 04, 2017) - Recent analysis of clinical development teams show that surveyed clinical teams are divided on whether or not companies should...
Clinical Teams From Top Pharma Companies Are Overcoming Challenges in Planning and Implementing Adaptive Trial Design Studies
July 19, 2017 19:23 ET | Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - July 19, 2017) - A recent study of Top 10, Top 50, and small medical device companies found that addressing regulators' concerns for late-stage studies is...